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Actin stress fiber organization promotes cell
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Studies of the role of actin in tumour progression have highlighted its key contribution in cell
softening associated with cell invasion. Here, using a human breast cell line with conditional
Src induction, we demonstrate that cells undergo a stiffening state prior to acquiring
malignant features. This state is characterized by the transient accumulation of stress fibres
and upregulation of Ena/VASP-like (EVL). EVL, in turn, organizes stress fibres leading to
transient cell stiffening, ERK-dependent cell proliferation, as well as enhancement of Src
activation and progression towards a fully transformed state. Accordingly, EVL accumulates
predominantly in premalignant breast lesions and is required for Src-induced epithelial
overgrowth in Drosophila. While cell softening allows for cancer cell invasion, our work reveals
that stress fibre-mediated cell stiffening could drive tumour growth during premalignant
stages. A careful consideration of the mechanical properties of tumour cells could therefore
offer new avenues of exploration when designing cancer-targeting therapies.
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B
reast cancer is a major cause of death in women world-
wide1. The multistep process of breast cancer progression
results from the acquisition of genetic and epigenetic
alterations in oncogenes and tumour suppressor genes, which
confer growth and/or survival advantage to mammary cells.
Subsequent molecular alterations may convert these premalignant
cells into malignant ones, with invasive and metastatic abilities2.
The viral non-receptor tyrosine kinase v-Src and its cellular
homologue c-Src are the most investigated proto-oncogenes,
implicated in many aspects of tumour development, including
proliferation, survival, adhesion, migration, invasion and metas-
tasis3. Src protein levels and, to a greater extent, Src protein
kinase activity are frequently elevated in malignant and non-
malignant breast tissues and significantly associated with
decreased survival of breast cancer patients4,5.
Src induces tumour metastasis mainly by reducing adhesive-
ness and by regulating the actin cytoskeleton3. The semi-flexible
polymers of filamentous actin (F-actin), which are assembled
from monomeric actin subunits (G-actin), exert or resist forces to
drive a large number of cellular processes, including changes in
cell shape, cell mobility, cytokinesis and intracellular transport.
In addition, actin filaments translate external forces into
biochemical signalling events that guide cellular responses6.
This has been largely studied in the context of tumour invasion
and malignancy, where mechanical signals from the tumour
microenvironment impact the metastatic cascade7. In turn,
metastatic breast cells have lower stiffness than their healthy
counterparts, which is largely determined by the cytoskeleton8,9.
To perform these different functions, actin filaments
organize into distinct architectures through the control of a
multitude of actin-binding proteins (ABPs) strongly conserved
between species10. Ena/VASP (enabled/vasodilator stimulated
phosphoprotein) family proteins, including protein-enabled
homologue (Mena), vasodilator-stimulated phosphoprotein
(VASP) and Ena-VASP-like (EVL), associate with barbed ends
of actin filaments. They appear to have different effects on
F-actin, including favouring actin filament elongation through
their anti-capping activity, inhibiting the formation of branched
actin networks and promoting F-actin bundling11. Accordingly,
Ena/VASP family members have distinct effects on cancer cell
migration and metastasis. While EVL suppresses cell migration12,
the Mena variant Mena (INV) drives invasion, intravasation and
metastasis13. Other ABPs inhibit actin polymerization or stabilize
actin filaments. In addition, some ABPs organize actin filaments
into higher-order networks, by cross-linking actin filaments, or
use F-actin as a scaffold, physical support or track, to promote
contractility and generate tension10.
We have previously reported that the pro-growth function of
Src is controlled by the actin cytoskeleton in Drosophila
epithelia14. In this report, we investigate the role of F-actin in
supporting the expansion of cancer precursors downstream of
Src. Using a breast cell line with conditional Src induction, we
demonstrate that prior to cells acquiring malignant features,
they undergo a transient stress-fibre-dependent stiffening state
leading to cell proliferation and the progression towards a fully
transformed state.
Results
Src sustains proliferation prior to inducing migration. The
main transformation events that occur upon overactivation of the
Src oncogene can be studied in cell culture, using the mammary
MCF10A epithelial cell model with conditional Src induction,
which contains a fusion between v-Src and the ligand-binding
domain of the Oestrogen Receptor (ER-Src), inducible with
tamoxifen (TAM) treatment15,16. ER-Src cells treated with the
vehicle EtOH, but not TAM-treated MCF10A cells carrying an
empty vector (PBabe; Supplementary Fig. 1), showed basal levels
of phosphorylated ER-Src (ER-pSrc), indicating that ER-Src
displays some degree of leakiness. However, treating ER-Src cells
with TAM potentiated ER-pSrc levels (Fig. 1a), which increased
in a stepwise manner during the 36 h of TAM treatment (Fig. 1b).
In addition, TAM treatment triggered the phosphorylation of
endogenously expressed Src (pSrc) (Fig. 1a). In two-dimensional
(2D) cultures, this untransformed cell line undergoes
morphological transformation features 36 h after TAM
treatment with progressive cell detachment (Fig. 1c and
Supplementary Movie 2). This is in contrast to ER-Src cells
treated with the vehicle EtOH (Fig. 1c and Supplementary
Movie 1) or PBabe cells treated with TAM (Supplementary
Fig. 1). In three-dimensional (3D) cultures of reconstituted
basement membrane, TAM but not EtOH treatment triggered
transformed features, characterized by the extrusion of cells from
the spherical acinar-like structure that invaded the Matrigel 45 h
after treatment (compare Supplementary Movies 3 and 4).
In the presence of serum and growth factors, TAM-treated
ER-Src cells did not display an increase in the percentage of
cells in S-phase of the cell cycle over EtOH-treated cells during
the 36 h of treatment (Supplementary Fig. 2). Consistent with a
requirement for epidermal growth factor (EGF) to support
proliferation of untransformed MCF10A cells17, in the absence
of EGF, the EtOH-treated ER-Src cell population showed a
progressive decrease in their proliferation rate over 36 h of
treatment. Cells that had been treated with TAM, however, had a
significant proliferation advantage over EtOH-treated cells,
starting 12 h after TAM treatment (Fig. 1d). Because cell
tracking showed no significant difference in velocity between
EtOH- and TAM-treated ER-Src cells during the first 12 h or
between 36 and 48 h of treatment (Supplementary Fig. 2), we
conclude that TAM-treated ER-Src cells acquire self-sufficiency in
growth properties before migrating abilities.
Src sustains cell proliferation in part via ERK activation. The
acquisition of self-sufficiency in growth properties is unlikely to
result from increased activity of the mediators of Hippo signal-
ling, Yes-associated protein (YAP) and transcriptional co-acti-
vator with PDZ-binding motif (TAZ), as we could not observe
YAP/TAZ being enriched in the nuclei of ER-Src cells grown in
the absence of serum and growth factors during the first 24 h of
TAM treatment (Supplementary Fig. 3). Moreover, microarray
analysis indicated that the YAP/TAZ target genes connective
tissue growth factor (CTGF), ankyrin repeat domain 1 (ANKRD1),
cysteine-rich angiogenic inducer 61 (CYR61), baculoviral IAP
repeat containing 5 (BIRC5), AXL receptor tyrosine kinase (AXL),
inhibin alpha subunit (INHA) and collagen type VIII alpha 1
chain (COL8A1) are not upregulated in TAM-treated ER-Src
cells18. Finally, quantitative PCR with reverse transcription 12
and 24 h after TAM treatment did not reveal higher CTGF or
ANKRD1 expression (Supplementary Fig. 3). As extracellular
signal-regulated kinases (ERK) have been shown to contribute to
EGF-independent growth of MCF10A cells19 and are important
contributors of tumour growth20, we tested the role of ERK in
Src-sustained proliferation. Accordingly, in the absence of serum
and growth factors, the levels of the phosphorylated form of ERK
(pERK) were significantly higher in ER-Src cells 12 h after TAM
treatment (Fig. 1e). Moreover, these cells upregulated Cyclin D1
(Fig. 1f), a known regulator of G1 to S phase progression20. ERK
is required to potentiate Cyclin D1 expression in these cells, as
co-treatment with PD184352, an inhibitor of the Mitogen-
activated protein kinase kinase (MEKi), strongly reduced pERK
levels in both EtOH- and TAM-treated cells at 12 h (Fig. 1g), but
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prevented the upregulation of Cyclin D1 exclusively in TAM-
treated cells (Fig. 1h). Furthermore, in the presence of serum and
growth factors, co-treatment of ER-Src cells with MEKi and
EtOH or TAM for 12 h reduced the percentage of S-phase,
compared to cells treated with DMSO (Fig. 1i). We conclude that
Src activation sustains cell proliferation by potentiating ERK
activation and Cyclin D1 upregulation.
Src transiently boosts F-actin assembly and cell stiffening. We
then investigated the effect of Src activation on F-actin when cells
acquire proliferative abilities. Strikingly, TAM-treated ER-Src
cells transiently accumulated basal actin fibres, mainly observed
12 h after Src induction (Fig. 2a and Supplementary Fig. 1).
Scoring of the percentage of cells with high basal F-actin signals
showed that only TAM treatment for 12 h significantly increased
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the fraction of cells with high basal F-actin levels (Fig. 2b).
Western blot analysis indicated that Src induction promoted a
significant increase in the ratio between F- and G-actin 12 h after
TAM treatment (Fig. 2c,d). Since total actin levels remained
constant during the transformation process (Fig. 2e), these
transient changes in F-actin are apparently due to an increase in
actin polymerization.
Higher absolute levels of F-actin or stress fibre formation have
been associated with increased cell stiffness, whereas a reduction
in F-actin or stress fibre disassembly correlates with lower cell
stiffness8,21,22. Accordingly, atomic force microscopy (AFM)-
based indentation measurements revealed that ER-Src (but not
PBabe) cells were significantly stiffer between 4 and 14 h after
TAM treatment compared to EtOH-treated cells (Fig. 2f and
Supplementary Fig. 1). In contrast, between 36 and 38 h,
when TAM-treated ER-Src cells displayed morphological
transformation features, they were more deformable than
control cells (Fig. 2f). Similarly, ER-Src cells isolated from
TAM-treated 3D cultures showed a transient increase in cell
stiffness at 12 h (Fig. 2g). However, cell stiffness was similar
between TAM- and EtOH-treated cells at 36 h (Fig. 2g). This may
be due to the fact that phenotypic transformation could take
longer in 3D cultures (Supplementary Movie 4). In accordance
with AFM experiments, real-time deformability cytometry
(RT-DC) measurements on suspended cells confirmed that
ER-Src cells were stiffer 12 h after TAM treatment (Fig. 2h).
Moreover, ER-Src cells treated with TAM for 12 h accumulated
higher levels of phospho-myosin light chain (pMLC) compared
to cells treated with EtOH for the same period of time (Fig. 2i).
Taken together, we conclude that Src-induced cellular
transformation involves a transient increase in actin fibres
associated with cell stiffening and the acquisition of self-
sufficiency in growth properties.
Common ABPs are deregulated by Src and in DCIS. To further
characterize the mechanisms leading to the transient increase in
F-actin and cell stiffness, we searched for ABPs involved in
building these F-actin structures. Microarray profiling identified
35 ABPs deregulated during the 36 h of Src-induced cellular
transformation (Fig. 3a)18. To test which of these ABPs would be
relevant for breast cancer progression, we analysed the expression
signature related to the actin cytoskeleton in premalignant
atypical ductal hyperplasia (ADH), ductal carcinoma in situ
(DCIS) and invasive ductal carcinoma (IDC) (Fig. 3b). Using
cancer expression data sets available from the GEO database, we
collected microarray data for 255 normal breast tissues and 903
neoplastic breast lesions, from which the available information
relative to the diagnosis, histological grade and ER status was
extracted (Supplementary Table 1). After normalization of the
raw data and statistical comparison of breast lesions with normal
breast tissues, we sorted all genes significantly deregulated
(Supplementary Data 1). As expected, classification of genes
into functional categories using Pathway Express indicated that
most of the significantly affected biological processes were
associated with cancer (Fig. 3b). Strikingly, ‘regulation of the
actin cytoskeleton’ was among the top 10 pathways significantly
deregulated in both premalignant lesions (ADH and DCIS). In
contrast, while IDCs upregulated many ABPs previously
implicated in cancer cell mobility23 (Supplementary Data 2),
the category ‘regulation of the actin cytoskeleton’ had a lower
impact factor in these malignant lesions relative to other
misregulated pathways or was not being significantly
affected (Fig. 3b). In addition, classification of these ABPs into
functional categories based on their role in F-actin dynamics
(Supplementary Data 2) showed that only malignant lesions were
enriched for inhibitors of polymerization (Supplementary Fig. 4).
Thus, major alterations in the expression of ABPs are
predominantly found in premalignant ADH and DCIS.
Among the 27 ABPs deregulated in premalignant ADH and/or
DCIS, EVL, Actin-related protein 3 (ACTR3), Actin-related
protein 2/3 complex subunit 5-like protein (ARPC5L), Dystronin
(DST), FH1/FH2 domain-containing protein 3 (FHOD3) and
Tropomyosin beta chain (TPM2) were also deregulated in TAM-
induced ER-Src cells (Fig. 3a)18. These ABPs may therefore affect
the expansion of TAM-treated ER-Src cells by regulating the
transient accumulation of actin fibres.
ABPs deregulated by Src impact tissue growth in Drosophila.
To investigate the effect of these ABPs in Src-induced prolifera-
tion, we first screened for those that affect the pro-growth func-
tion of Src in Drosophila, as this organism contains only one
family member for each of these ABPs (Supplementary Table 2),
reducing the risk of gene redundancy. As expected, distal wing
discs overexpressing Drosophila Src oncogene at 64B (Src64B)
together with the Caspase inhibitor p35 and Green fluorescent
protein (GFP) using the the Nubbin-Gal4 (Nub-Gal4) driver were
significantly bigger than control discs expressing GFP only
(Fig. 4a,b). Strikingly, replacing UAS-GFP by a UAS construct
expressing double-strand RNA (dsRNA) directed against EVL/
Ena in Nub4Src/p35 wing discs fully suppressed tissue over-
growth (Fig. 4a,b and Supplementary Table 2). In contrast,
knocking down ACTR3/Arp3, ARPC5L/Arpc5, DST/Shot,
FHOD3/Fhos or TPM2/Tm2 enhanced the overgrowth of
Nub4Src/p35-expressing wing discs (Supplementary Table 2 and
Supplementary Fig. 5). In the converse experiments, over-
expressing EVL/Ena strongly enhanced Src-induced tissue over-
growth (Fig. 4a,b and Supplementary Table 2), while
overexpressing ACTR3/Arp3 or DST/Shot or an activated form of
Fhos deleted of the conserved C terminal basic cluster (EGFP-
Fhos-bB) reduced the overgrowth of these tissues (Supplementary
Table 2 and Supplementary Fig. 5). These observations suggest
that EVL/Ena promotes Src/p35-induced tissue overgrowth, while
Figure 1 | ERK sustains proliferation of TAM-treated ER-Src cells at 12 h. (a) Western blots on protein extracts from ER-Src cells treated with EtOH or
TAM for 4, 12, 24 or 36 h, blotted with anti-pSrc, which reveals ER-pSrc or endogenous pSrc or anti-GAPDH. (b) Ratio of ER-pSrc levels between TAM- and
EtOH-treated ER-Src cells for the same time points, normalized to GAPDH. (c) Images by phase contrast microscopy of ER-Src cells, treated with TAM or
EtOH for 4, 12, 24 or 36 h. Scale bars, 50mm. (d) Percentage of ER-Src cells in S-phase after treatment with EtOH (grey bars) or TAM (orange bars) for 4,
12, 24 or 36 h in the absence of EGF. (e) Western blots on protein extracts from ER-Src cells treated with EtOH or TAM for 12 h, blotted with anti-pERK or
anti-ERK, and quantification of the ratio of pERK over total ERK levels, normalized to GAPDH for the corresponding lane on western blots. EtOH treatment
(grey bar), TAM treatment (orange bar). (f) Cyclin D1 mRNA levels on extracts from ER-Src cells treated with EtOH (grey bar) or TAM (orange bar) for
12 h. (g) Western blots on protein extracts from ER-Src cells treated with EtOH or TAM and DMSO or MEKi for 12 h, blotted with anti-pERK or anti-ERK,
and quantification of the ratio of pERK over total ERK levels, normalized to GAPDH for the corresponding lane on western blots. (h) Cyclin D1 mRNA levels
on protein extracts from ER-Src cells treated with EtOH or TAM and DMSO or MEKi. (i) Number of ER-Src cells in S-phase treated with EtOH or TAM and
DMSO or MEKi. DMSO treatment (grey bars), MEKi treatment (blue bars). Quantifications are from (a) six or (c–h) three biological replicates. Error bars
indicate s.d.; NS indicates non-significant; *Po0.05; **Po0.001; ***Po0.0001. Statistical significance was calculated using (d) two-way ANOVA or (e,f)
impaired t-test or (b,g–i) one-way ANOVA. See also Supplementary Figs 1–3 and 7, and Supplementary Movies 1–4.
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Figure 2 | Transient F-actin accumulation and cell stiffening by Src activation. (a) Standard confocal sections of ER-Src cells treated with TAM for 4, 12,
24 or 36 h, stained with Phalloidin (magenta) to mark F-actin, anti-p-Src (cyan) and DAPI (blue). Scale bars, 10 mm. (b) Percentage of ER-Src cells with high
F-actin levels, treated with EtOH (black dots) or TAM (orange dots) for 4, 12, 24 or 36 h. Each dot represents one technical replicate from two biological
replicates. Horizontal line indicates median values. (c) Western blot on protein extracts from ER-Src cells treated with EtOH or TAM for 4, 8, 12, 24 or 36 h,
blotted with anti-actin. (d) Quantification from three biological replicates of the G- (grey) and F-actin (magenta) ratio in EtOH- or TAM-treated ER-Src cells
for the time points indicated. (e) Western blots on protein extracts from ER-Src cells treated with EtOH or TAM for 4, 12, 24 or 36 h, blotted with anti-actin
and anti-GAPDH, and quantification from three biological replicates of the ratio of total actin levels between TAM- and EtOH-treated ER-Src cells for the
same time points, normalized to GAPDH for the corresponding lanes on western blots. (f–h) Apparent Young’s moduli of ER-Src cells, treated with EtOH
(grey bars) or TAM (orange bars) for the time points indicated, measured by (f,g) AFM in f 2D or (g) 3D, or by (h) RT-DC. Data are from three (f) or two
(g,h) biological replicates and are presented as boxplots (25th, 50th, 75th percentiles) and whiskers indicating 10th and 90th percentiles. (i) Western blots
on protein extracts from ER-Src cells treated with EtOH or TAM for 12 h, blotted with anti-pMLC or anti-GAPDH, and quantification from three biological
replicates of pMLC levels, normalized to GAPDH for the corresponding lane on western blots. EtOH treatment (grey bar), TAM treatment (orange bar).
Error bars indicate s.d.; NS indicates non-significant; *Po0.05; **Po0.001; ***Po0.0001. Statistical significance was calculated using (b–e) one-way
ANOVA or (f,g) simple Mann–Whitney or (h) linear mixed models or (i) impaired t-test. See also Supplementary Fig. 1.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15237 ARTICLE
NATURE COMMUNICATIONS | 8:15237 | DOI: 10.1038/ncomms15237 | www.nature.com/naturecommunications 5
Im
pa
ct
 fa
ct
or
ER– IDC3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Im
pa
ct
 fa
ct
or
ER- IDC2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
ER+ IDC3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Im
pa
ct
 fa
ct
or
ER+ IDC2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Im
pa
ct
 fa
ct
or
ER+ IDC1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Im
pa
ct
 fa
ct
or
ER+ DCIS
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Im
pa
ct
 fa
ct
or
ER+ ADH
1 2 3 4 5 6 7 8 9 10 11 12 13
Im
pa
ct
 fa
ct
or
a
AD
H
DC
IS
IDC
1
IDC
2
IDC
3
–
3
–
1 0
+
1
–
2
Fold changes1 h 2 h 4 h 8 h 12
 h
16
 h
24
 h
36
 hER-Src
TAM
b
ACTN1
ACTR3
ARPC5L
CAP1
CLMN
EVL
FLNB
KLHL2
LCP1
LIMA1
MACF1
MICAL1
MSN
MYH9
EVL
Focal adhesion
Adherens junction
Melenoma
Prostate cancer
Melanogenesis
Wnt signaling pathway
Pathway in cancer
Regulation of actin cytoskeleton
15
10
5
0
15
10
5
0
0
10
20
30
40
0
10
20
30
40
50
0
10
10
8
6
4
2
0
100
80
60
40
20
0
20
30
40
50
Acute myeloid leukaemia
Basal cell carcinoma
Bolorectal cancer
Bladder cancer
Epithelial cell signaling in Helicobacter pylori infection
Axon guidance
Protein export
Renal cell carcinoma
Pancreatic cancer
p53 signaling pathway
Glioma
DNA replication
Vibrio cholerae infection
Ubiquitin-mediated proteolysis
SNARE interactions in vesicle transport
Renal cell carcinoma
Endometrial cancer
TGF-beta signaling pathway
Insulin signaling pathway
B cell receptor signaling pathway
Non-small cell lung cancer
MAPK signaling pathway
Adipocytokine signaling pathway
VEGF signaling pathway
ErbB signaling pathway
ABC transporters
Complement and coagulation cascades
Small cell lung cancer
Chronic myoloid leukaemia
Proteasome
Mismatch repair
Base excision repair
mTOR signaling pathway
Notch signaling pathway
Maturity onset diabetes of the young
Type I diabetes mellitus
Calcium signaling pathway
Hematopoietic cell lineage
Allograft rejection
Leukocyte transendothelial migration
Parkinson’s disease
Apoptosis
T cell receptor signaling pathway
Ribosome
Systemic lupus erythematosus
Homologous recombination
Type II diabetes mellitus
Thyroid cancer
Cell cycle
ECM-receptor interaction
Tight junction
ACTR3
ACTR3
ARPC3
ARPC5L
CAPZA1
CFL1
ENAH
EVL
EZR
GMFB
LASP1
MARCKSL1
MICAL2
MYO6
PLS1
SHROOM2
CORO2B
DST
FHOD3
MYH3
MYLK
MYO9A
PARVA
SNTA1
SNTB2
TAGLN
TMOD1
TPM2
ARPC5L
DST
FHOD3
TPM2
MYO1E
SSFA2
STK38L
UTRN
ABLIM3
ADD3
ARPC2
CALD1
CAMK2B
COTL1
DMD
DST
DSTN
FHOD3
LASP1
MYH10
PFN2
PLS3
TNNI2
TPM2
TRIOBP
N
or
m
al
AD
H
D
CI
S
ID
C
Figure 3 | Microarray analysis of breast lesions and TAM-treated ER-Src cells. (a) Heatmaps of ABP deregulated in (left panel) ER-Src cells treated with
TAM for the different time points indicated18 or (right panel) ADH and/or DCIS and their expression in the three IDC grades (IDC1, IDC2, IDC3).
Fold-changes are in Log2R. (Middle panel) Common ABPs misregulated in the same direction in ADH/DCIS and in TAM-treated ER-Src cells. Orange and
blue indicate genes up- and downregulated, respectively. (b) (Left) Schematic of the multistep model of breast cancer progression. (Right) Pathway impact
analysis for the sets of genes differentially expressed in ERþ ADH, ERþ DCIS, ERþ IDC1, ERþ IDC2, ERþ IDC3, ER IDC2 and ER IDC3 when
compared to normal breast tissue samples. All pathways significantly affected were plotted on the basis of their impact factor. Black arrows indicate the
‘Regulation of actin cytoskeleton’ pathway (magenta). See also Supplementary Table 1, Supplementary Data 1 and 2 and Supplementary Fig. 4.
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ACTR3/Arp3, ARPC5L/Arpc5, DST/Shot, FHOD3/Fhos and
TPM2/Tm2 could have the opposite effect.
Quantification of the ratio between the Nub4GFP-expressing
area and the total wing disc area showed that overexpressing
EVL/Ena (Fig. 4c) or knocking down DST/Shot or TPM2/Tm2
was sufficient to induce the overgrowth of wing discs that did
not overexpress Src and p35 (Supplementary Table 2 and
Supplementary Fig. 5). Surprisingly, expressing EGFP-Fhos-bB
also triggered overgrowth of control Nub4GFP wing discs
(Supplementary Table 2 and Supplementary Fig. 5), suggesting
that the effect of Fhos on tissue growth depends on the cellular
context. In contrast, overexpressing DST/Shot significantly
reduced the growth of these tissues (Supplementary Table 2
and Supplementary Fig. 5). Strikingly, EVL/Ena accumulated in
the posterior compartment of wing discs overexpressing Src
together with p35 and GFP (Fig. 4e–e00), but not in those
expressing p35 and GFP only (Fig. 4d–d00). Accordingly,
quantification by western blot indicated that EVL/Ena levels
were four times higher in wing discs extracts overexpressing
Src and p35 under Scalloped-Gal4 (Sd-Gal4) control, compared
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Figure 4 | Drosophila EVL/Ena promotes Src-induced tissue overgrowth. (a) Standard confocal sections of third instar wing imaginal discs with dorsal
side up, stained with Phalloidin (magenta). (Left column) nub-Gal4; UAS-p35 or (middle column) nub-Gal4, UAS-p35, Src64BUY1332 or (right column) nub-
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NS, indicates non-significant for comparison with Nub4GFP,p35. Error bars indicate s.d. ***Po0.0001. (d–d00 and e–e00) Standard confocal sections of third
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nub-Gal4 (lane 3), blotted with anti-Ena and anti-a-Tubulin (a-Tub). (g) Quantification from three biological replicates of the ratio of Ena levels normalized
to a-Tub for the genotypes indicated. Error bars indicate s.d. ***Po0.0005. Statistical significance was calculated using the impaired t-test. See also
Supplementary Fig. 5 and Supplementary Table 2.
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to discs expressing p35 and GFP (Fig. 4f,g). We conclude that
in vivo EVL/Ena accumulates upon Src activation and is
necessary to promote Src-induced tissue overgrowth.
EVL potentiates ERK-sustained cell proliferation. We then
tested whether EVL was also required for the proliferation of
TAM-treated ER-Src cells. Consistent with the upregulation of
EVL on microarrays (Fig. 3), EVL protein transiently accumu-
lated 12 and 24 h after TAM treatment (Fig. 5a,b). Knocking
down EVL using two independent short-hairpin RNA (shEVL),
significantly reduced EVL mRNA and protein levels, as well as
cell growth, in ER-Src cells treated with EtOH or TAM for 36 h
in the presence of serum and growth factors, compared to
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cells transfected with a scrambled short-hairpin RNA (shScr)
(Supplementary Fig. 6). In the absence of serum and growth
factors, EVL expression was significantly increased 12 h after
TAM treatment in ER-Src cells transfected with shScr (Fig. 5c).
This increase in EVL mRNA levels was significant reduced in cells
transfected with shEVL. However, EtOH-treated ER-Src cells
transfected with shEVL did not show a significant reduction of
EVL expression at 12 h (Fig. 5c), suggesting that in the absence
of serum and growth factors, ER-Src cells express low EVL levels.
In these culture conditions, knocking down EVL in ER-Src cells
treated with TAM for 12 h reduced the increase in pERK levels
(Fig. 5d,e) without affecting total ERK levels (Fig. 5d) and
inhibited the upregulation of Cyclin D1 (Fig. 5f). Knocking down
EVL also lowered the number of ER-Src cells in S-phase 12 h after
TAM treatment. However, it had no significant effect on cells
treated with EtOH for the same period of time (Fig. 5g). Thus, the
upregulation of EVL by Src activation potentiates ERK-induced
cell proliferation early during cellular transformation.
EVL is also required for TAM-treated ER-Src cells to progress
toward a fully transformed phenotype, as knocking down
EVL fully suppressed the invasive spike-like phenotype of
TAM-treated acini grown in the presence of serum and growth
factors for 14 days (Fig. 5h). These acini were significantly smaller
than EtOH-treated acini (Fig. 5i), likely due to the fact that
TAM-treated cells did not increase their proliferation rate in the
presence of serum and growth factors (Supplementary Fig. 2), as
well as, extruded from the spherical acini-like structure
(Supplementary Movie 4). Consistent with a role of EVL in
promoting cell growth in the presence of serum and growth
factors (Supplementary Fig. 6), EVL knockdown reduced the size
of EtOH-treated ER-Src acini (Fig. 5i). EVL is also required for
the tumorigenic potential of Src, as knocking down EVL inhibited
the ability of TAM-treated ER-Src cells to produce anchorage-
independent colonies in the absence of EGF (Fig. 5j,k). Finally,
knocking down EVL in ER-Src cells treated with TAM for 12 h
reduced ER-pSrc levels (Fig. 5l), indicating that EVL potentiates
Src activity. Altogether these observations demonstrate that EVL
is required for Src-dependent ERK activation, which upregulates
Cyclin D1 and sustains cell proliferation. In addition, EVL
potentiates Src activation and the progression towards a fully
transformed phenotype.
Stress fibres and cell stiffening induced by Src require EVL. We
next tested whether EVL sustains the proliferation of TAM-
treated ER-Src cells by assembling the transient Src-dependent
actin fibres at 12 h. These F-actin-based structures were largely
stained by cytoplasmic b-actin (b-CYA), which predominantly
localizes in stress fibres24, but not by cytoplasmic g-actin
(g-CYA) (Fig. 6a). Moreover, the Src-dependent actin fibres
were associated with larger focal adhesions (FAs), seen by
staining with Paxillin (Fig. 6c) and were enriched for pMLC
(Fig. 1d), suggesting that they are likely ventral stress fibres.
Consistent with a role of EVL in assembling these stress fibres,
EVL accumulated at their tips (Fig. 6b). However, knocking down
EVL did not suppress the ability of TAM-treated ER-Src cells to
form larger FAs at 12 h (Fig. 6c), nor to accumulate F-actin
(Fig. 6e,f). On the contrary, EVL knockdown triggered
significantly higher amounts of the F-actin pool in EtOH-
treated cells (Fig. 6e,f). Quantification of stress fibres anisotropy
indicates that 12 h after TAM treatment, ER-Src cells expressing
shScr, showed an anisotropic fibre arrangement, compared to
those treated with EtOH (Fig. 6g). Strikingly, knocking down
EVL in these cells fully suppressed the increase in fibre anisotropy
(Fig. 6g). Stress fibre organization by EVL impacts the stiffening
of TAM-treated ER-Src cells, as knocking down EVL in these cells
prevented their increased cell stiffening at 12 h (Fig. 6h). In
addition, knocking down EVL limited the accumulation of
pMLC loaded on the Src-dependent stress fibres 12 h after TAM
treatment (Fig. 6d). Taken together, we conclude that during the
first 12 h of cellular transformation, organization of the Src-
dependent stress fibres by EVL promotes cell stiffening, cell
proliferation and the progression towards a fully transformed
phenotype.
Cell stiffening potentiates ERK and Src activities. To test the
possibility that the EVL-dependent polarized stress fibres sustain
cell proliferation by promoting cell stiffening, we inhibited
Myosin II activity in ER-Src cells using Blebbistatin (Blebb). As
expected, ER-Src cells co-treated with Blebbistatin and EtOH or
TAM for 12 h reduced their stiffness, compared to those treated
with DMSO (Fig. 7a). Moreover, Blebbistatin treatment reduced
the increase in pERK levels (Fig. 7b,c), as well as the upregulation
of Cyclin D1 (Fig. 7d) in ER-Src cells treated with TAM for 12 h
in the absence of serum and growth factors. Furthermore,
co-treatment of ER-Src cells with Blebbistatin and EtOH or TAM
in the presence of serum and growth factors reduced the per-
centage of S-phase, compared to cells treated with DMSO
(Fig. 7e). Finally, Myosin II activity is also required for the
stepwise increase of Src activity, as ER-Src cells co-treated with
TAM and Blebbistatin for 12 h showed reduced ER-pSrc levels
compared to ER-Src cells treated with TAM and DMSO for the
same period of time (Fig. 7f). We conclude that Myosin
II-dependent cell stiffening is required to potentiate ERK activity
and Cyclin D1 expression, and to further enhance Src activity.
These observations support a role for the EVL-dependent
polarized stress fibres in mediating the proliferative-promoting
ability of Src via cell stiffening.
Figure 5 | EVL sustains Src-induced proliferation via ERK activation. (a) Western blots on protein extracts from ER-Src cells treated with EtOH or TAM
for 4, 12, 24 or 36 h, blotted with anti-EVL and anti-GAPDH (see original blot in Supplementary Fig. 6A). (b) Ratio of EVL levels between TAM- and
EtOH-treated ER-Src cells for the same time points, normalized to GAPDH. (c) EVL mRNA levels on extracts from ER-Src cells expressing shScr or
shEVL#2 and treated with EtOH or TAM for 12 h. (d) Western blots on protein extracts from ER-Src cells expressing shScr or shEVL#2 and treated with
EtOH or TAM for 12 h, blotted with anti-pERK or anti-ERK or anti-GAPDH, and quantification of total ERK levels between EtOH- and TAM-treated cells,
normalized to GAPDH for the corresponding lanes on western blots. (e) Ratio of pERK over total ERK levels, normalized to GAPDH for the experimental
conditions indicated. (f,g) Cyclin D1 mRNA levels (f) or number of cells in S-phase (g) for ER-Src cells expressing shScr or shEVL#2 and treated with EtOH
or TAM for 12 h. (h) 14-day cultures on Matrigel of EtOH- or TAM-treated ER-Src acini, expressing shScr or shEVL#2. Scale bars represent 50mm. (i)
Quantification from two biological replicates of acini size for the experimental conditions indicated. Horizontal lines indicate median values. (j) Phase-
contrast images of ER-Src colonies grown in soft agar without EGF, expressing shScr or shEVL#2 and treated with EtOH or TAM. Inset images correspond
to a 135% magnification. (k) Number of colonies for the experimental conditions indicated. (l) Western blots on protein extracts from ER-Src cells
expressing shScr or shEVL#2 and treated with EtOH or TAM for 12 h, blotted with anti-pSrc to reveal ER-pSrc or anti-GAPDH, and quantifications of ER-
pSrc levels, normalized to GAPDH for the corresponding lanes on western blots. shScr treatments (grey bars), shEVL treatments (green bars).
Quantifications are from three biological replicates, unless indicated. Error bars indicate s.d.; NS indicates non-significant; *Po0.05; **Po0.001;
***Po0.0001. Statistical significance was calculated using (b) a Friedman or (c–l) one-way ANOVA tests. See also Supplementary Fig. 6.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15237 ARTICLE
NATURE COMMUNICATIONS | 8:15237 | DOI: 10.1038/ncomms15237 | www.nature.com/naturecommunications 9
EVL accumulates in premalignant DCIS. To evaluate EVL
expression in breast cancer progression, we performed immu-
nohistochemistry in a series of human breast tissues comprising
normal breast, DCIS and IDCs. Consistent with its role in F-actin
regulation, EVL mainly localized to the cytoplasm in all samples
analysed and could also be observed accumulated at the cell
periphery (Fig. 8a and Table 1A). In normal breast, EVL
expression was low with only 4.2% (1/24 cases) of the cases being
scored as positive and was mainly found in luminal cells. Strik-
ingly, EVL levels were significantly higher in DCIS and IDC
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Figure 6 | The Src-dependent stress fibres and cell stiffening require EVL. (a) Standard confocal sections of ER-Src cells treated with TAM or EtOH for
12 h and stained with b-CYA (magenta) and g-CYA (green). (b) Standard confocal sections of ER-Src cells treated with TAM for 12 h and stained with
Phalloidin (magenta), anti-EVL (green) and DAPI (blue). (c,d) Standard confocal sections of ER-Src cells treated with TAM or EtOH for 12 h, expressing
shScr or shEVL#2, stained with Phalloidin (magenta), DAPI (blue) and (c) anti-Paxillin (yellow) or (d) anti-pMLC (yellow). All scale bars represent 10mm.
(e) Western blot on protein extracts from ER-Src cells treated with EtOH or TAM for 12 h, expressing shScr or shEVL#2, blotted with anti-actin to visualize
the G- and F-actin pools. (f) Quantification of the G- (grey) and F-actin (magenta) ratio for the experimental conditions indicated. (g) Anisotropy of stress
fibres in ER-Src cells expressing shScr (grey dots) or shEVL#2 (green dots) and treated with EtOH or TAM for 12 h. Each dot represents the anisotropy of
single cells, with the horizontal line indicating median values. (h) Apparent Young’s moduli of ER-Src cells expressing shScr (grey bars) or shEVL#2
(green bars) and treated with EtOH or TAM for 12 h. Data are presented as boxplots (25th, 50th, 75th percentiles), and whiskers indicate the 10th
and 90th percentiles. All quantifications are from three biological replicates. Error bars indicate s.d.; NS indicates non-significant; *Po0.05; **Po0.001;
***Po0.0001. Statistical significance was calculated using (f,g) one-way ANOVA or (h) the Kruskal–Wallis test.
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lesions, with 56.0% (51/91) and 40.7% (61/150) classified as
positive in DCIS and IDC, respectively. Interestingly, IDC pre-
sented significantly reduced EVL expression compared to DCIS
(Fig. 8a and Table 1A). Indeed, when considering all cases where
in situ and invasive compartments were found simultaneously on
the same slide, we observed a significant reduction in EVL
expression from the in situ to the invasive counterpart in 54.9%
(39/71) of the cases. Only 11.3% (8/71) of the cases showed higher
EVL levels in the invasive compartment and 33.8% (24/71)
showed no changes in EVL expression (Fig. 8b).
We then investigated in this series of human breast tumours, if
the presence of high EVL levels correlates with specific
clinicopathological features. Consistent with our microarray
analysis of breast tumour samples, in which EVL was found
upregulated in ERþ breast lesions (Supplementary Data 1 and 2),
high EVL expression was positively associated with the expression
of ER, in both DCIS and IDC, with the luminal A molecular
subtype, the absence of epidermal growth factor receptor 2
(HER2) expression, the negative expression of the two basal
markers cytokeratin 5 (CK5) and P-cadherin (P-cad) in DCIS
lesions, and with low-grade DCIS and grade I IDC (Table 1B and
Supplementary Table 3). Taken together, these observations are
consistent with a requirement of high EVL levels for the
development of premalignant breast lesions.
Discussion
In this manuscript, we show that early during cellular
transformation, low Src activity promotes stress fibre assembly
and upregulates EVL. Stress fibre organization by EVL leads to
cell stiffening, ERK activation, Cyclin D1 upregulation, sustained
cell proliferation, as well as, enhanced Src activation and the
progression towards a fully transformed state. Later during
transformation, higher Src activity, in addition to a reduction in
EVL levels would disassemble stress fibres to facilitate cell
migration (Fig. 9).
In agreement with previously observations25, Src triggers stress
fibre disassembly that would allow for cell migration and
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invasion. Like in 3D, the acquisition of migrating abilities in
monolayer cultures may require the presence of activated Src for
45 h. Alternatively, migrating TAM-treated ER-Src cells could be
those that detached from the substratum. Like in invasive cancer
cells8,26, this reduction in F-actin is associated with higher mean
deformability. However, our work also reveals that earlier during
transformation, Src has opposite effects on stress fibre assembly
and cell stiffening, which correlate with the upregulation of
Cyclin D1 by ERK activation and the acquisition of proliferative
abilities. These cells assemble larger FAs and transient associated-
acto-myosin stress fibres, reminiscent to the accumulation of
actin-containing microfilament bundles previously reported in
chick embryo fibroblasts with conditional Src induction27.
Accordingly, Src is known to activate the Rho-associated,
coiled-coil containing protein kinase (ROCK), which promotes
acto-myosin contractility28. The apparently opposite effects of Src
on stress fibres and cell stiffening correlates with a stepwise
increase in Src activity levels and the successive acquisition of
premalignant and malignant features in ER-Src cells, as well as in
some cancers, such as those of the colon29–32. Thus, while low Src
activity would promote stress fibre-mediated cell stiffening
accompanying tumour growth, higher levels would have the
opposite effect, allowing for cell migration.
While Ena/VASP proteins have been proposed to act as anti-
capping proteins to permit filament elongation11, we show
here that EVL restricts F-actin accumulation in untransformed
ER-Src cells or localizes at the tip of the transient Src-dependent
stress fibres to organize them into polarized actin networks and to
promote cell stiffening. Thus, EVL may have distinct effects on
F-actin depending on the cellular context. Accordingly, several
reports describe additional mechanisms by which Ena/VASP
proteins regulate F-actin, including preventing branching by
the Actin-related protein 2/3 complex (Arp2/3), promoting
bundling and recruiting profilin-G-actin complexes11,33–36.
In untransformed ER-Src cells, EVL may therefore limit Arp2/3
recruitment to F-actin. In contrast, Src-activated cells undergoing
transformation may use EVL to cluster stress fibre barbed
ends, favouring their bundling along actin filament length.
However, we cannot exclude that EVL-dependent nucleation
of a sub-population of actin filaments promotes stress fibre
organization and cell stiffening. Our observations also argue
that stress fibre accumulation per se, or an increase in F-actin
content, is not sufficient to predict an increase in cell stiffness. As
previously proposed37–39, cellular contractility is also dependent
of the spatial organization of stress fibres, with EVL being a key
player in this context.
We propose that by supporting acto-myosin contractility, EVL
provides a proliferative advantage to cell undergoing transforma-
tion. Accordingly, we show that EVL and Myosin II activity
potentiates ERK activation, which, in turn, upregulates Cyclin D1
and sustains cell proliferation. ERK overactivation and Cyclin D1
overexpression have been observed in several cancers, including
those of the breast, and act as important regulators of tumour
cell proliferation20,40. Moreover, EVL accumulates predominantly
in premalignant breast lesions and its upregulation has been
associated with the proliferation of mesothelial cells by glucose
degradation product41. Furthermore, tumours are frequently
detected as rigid masses with cells showing an increase in the
elastic modulus resulting from an altered cytoskeleton42. Finally,
the growth of uterine sarcoma, prostate, lung and breast tumour
cells can be prevented using a ROCK inhibitor43. Forces applied
to stress fibres could directly alter ERK conformation, favouring
its activation via phosphorylation. Accordingly, integrin-
mediated organization of the actin cytoskeleton regulates
ERK nuclear translocation and activity44,45. Similarly,
mechanical stretch transmitted along the actin cytoskeleton can
activate Src46, justifying the stepwise increase in ER-pSrc levels
potentiated by EVL and Myosin II activity and the increase in
endogenous pSrc. This positive feedback mechanism on Src
would be expected to cause the subsequent decrease in
stress fibre-dependent contractility allowing for cell migration.
However, we cannot exclude that the effect of inhibiting Myosin
II activity on ERK-dependent cell proliferation is independent of
the polarized stress fibres by EVL, as Myosin II activity controls
several essential cellular processes47.
Our observations also show that in the presence of serum and
growth factors, EVL is required for the growth of untransformed
ER-Src cells and suggest that the failure of these cells to
proliferate in the absence of growth factors could be due, in
part, to the lack of EVL expression. The upregulation of EVL by
Src activation would therefore assure that cells acquire self-
sufficiency in growth properties. However, how EVL promotes
the growth of untransformed ER-Src cells is unclear, as EVL do
not appear to control stress fibres organization, nor cell stiffening
in these cells.
In addition to EVL, other ABPs might be involved downstream
of Src to sustain cell proliferation. DST, FHOD3 and TPM2, may
limit tumour growth. Accordingly, a large number of cancers,
including those of the breast, downregulate TPM2 (ref. 48).
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Figure 8 | EVL predominantly accumulates in DCIS. (a) Representative
images of EVL staining by IHC in normal breast tissues, DCIS and IDC,
and quantification of EVL protein expression at each stage. *P¼0.023;
***Po0.0001. Statistical significance was calculated using Fisher’s
exact test. Values are from visual scores±s.e.m. Scale bars represent
100mm. Images on the right are magnifications of the boxed areas.
(b) Representative image of EVL staining by IHC from the same breast
carcinoma sample containing both an in situ and an invasive component
and quantification (71 cases). Scale bar represents 100mm.
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Furthermore, restoration of TPM1 and 2 expression in Ras-
transformed cells suppresses the transformed phenotype49.
Surprisingly, while the Arp2/3 complex is known for promoting
cancer cell mobility and invasiveness50, ACTR3 and ARPC5L
restrict Src-induced tissue overgrowth in vivo. As Arp2/3 controls
a multitude of cellular functions51, it may have opposite functions
in tumour growth and invasion/metastasis, respectively. Further
studies would be required to confirm the role of these ABPs in
tumour growth.
Mouneimne and collaborators have proposed that low EVL
levels are predictive of highly invasive tumours and poor
prognosis12. Accordingly, EVL restricts the migratory ability of
MCF10A and untransformed ER-Src cells, as well as SUM159
breast cancer cells12. This would justify the need for reducing
EVL levels in TAM-treated ER-Src cells that acquire invading
abilities16, as well as in IDCs. However, our observations also
reveal that high EVL levels could be a significant predictor of
Src-induced breast tumour expansion at earlier stages. Mena11a,
another Ena/VASP variant, is also overexpressed in a subset of
benign breast lesions associated with HER2 positivity, while
downregulated in invasive cells and increases the proliferation
rate of MCF-7 cells52,53. Thus, several members of the Ena/VASP
family could have similar functions in tumour progression.
Surprisingly, while Src correlates with ER and HER2 expression
and triple negativity54, EVL is associated with the absence of
HER2, the expression of ER and with the luminal A molecular
subtype. Thus, EVL may only be required for the growth of a
subset of breast tumours that contain high Src activity. Whether
in non-Luminal A breast tumours, Src promotes tumour
expansion via other ABPs, such as Mena11a is an interesting
possibility to be tested in the future. Overall, our work places
actin regulation and cell rigidity as central contributors to all
stages of in the evolution of breast cancer, which opens new
avenues of exploration when designing cancer-targeting therapies.
Methods
Normalization and statistical analysis of microarray data. Raw data (CEL files)
from 16 publicly available microarray series were collected from the Gene
Expression Omnibus (GEO) database of National Center for Biotechnology
Information (NCBI). Both Affimetrix platforms used cover an identical set of
154 genes encoding ABPs. For other genes, only probesets present in both
Affimetrix platforms were analysed. R Programming Language for Statistical
Computing 2.14.1 (22-12-2011) along with Bioconductor 2.10 packages was used
to perform all the calculations55. Raw data were subjected to the frozen Robust
Multi-Array Average (fRMA) algorithm56, followed by summarization based on
multi-array model, fitted using the Median Polish algorithm. ComBat algorithm57
was used to decrease the non-biological experimental variation or batch effect for
each gene independently. Expression values were transformed in log2, and
probesets were mapped using the Entrez gene probeset definition58. The Pathway-
Express tool from the Onto-tools (http://vortex.cs.wayne.edu) was used to assess
biological processes and pathways affected at different stages of ERþ breast
tumour samples. Genes encoding for human ABPs were selected from the
UNIPROT database on January 2013, using the following key words: ‘actin-binding
protein’; Organism: ‘9606’; localized on ‘cytoskeleton’; reviewed: ‘yes’. The list was
verified based on the presence of an actin-binding domain.
Fly strains and genetics. Fly stocks used were nub-Gal4 (ref. 59),
sd-Gal4 (ref. 60), Src64BUY1332 (ref. 61); UAS-p35 (ref. 62), UAS-arp3-IRKK108951,
UAS-arpc5-IRKK102012, UAS-Tm2-IRKK107970, UAS-fhos-IRGD10435 (Vienna
Drosophila Research Center , VDRC), UAS-ena-IRJF01155, UAS-enaS187A (ref. 63)
UAS-shot-IRGL01286, UAS-GFP::arp3 (ref. 64), UAS-ena (ref. 65); UAS-shotL(A)-
GFP (ref. 66), UAS-EGFP-fhosDB (ref. 67). All crosses were maintained at 25 C.
Male and female larvae were dissected at the end of the third instar.
Cell lines, culture conditions and drug treatments. The MCF10A-ER-Src
(ER-Src) and MCF10A-PBabe (PBabe) cell lines were kindly provided by
K. Struhl15. The presence or absence of the ER-Src fusion construct was confirmed
by PCR in the ER-Src and PBabe cells using three independent pairs of primers
(50-Src-ERB GGGAGCAGCAAGAGCAAGCCTAAG and 30-Src-ERB CGGGGG-
TTTTCGGGGTTGAGC or 50-Src-ERF GTGGCTGGCTCATTCCCTCACTACA
and 30-Src-ERF GCACCCTCTTCGCCCAGTTGA or 50-Src-ERE AGAGGGTGC-
CAGGCTTTGTG and 30-Src-ERE GGGCGTCCAGCATCTCCAG). The presence
of Mycoplasma contamination was tested in both cell lines by PCR using the
primers 50-ACTCCTACGGGAGGCAGCAGT-30 and 50-TGCACCATCTGTCAC-
TCTGTTAACCTC-30 , which amplifies the spacer regions between the 16S and
23S ribosomal RNA genes. None of the cell lines tested positive for Mycoplasma
contamination. Cells were grown in a humidified incubator at 37 C, under a
5% CO2 atmosphere in DMEM/F12 growth medium (Invitrogen, 11039-047),
supplemented with 5% horse serum (Invitrogen 16050-122), previously stripped of
hormones through dextran-coated charcoal incubation (Sigma C6241), 20 ng per
ml of EGF (Peprotech, AF-100-15), 10 mg per ml of insulin (Sigma, I9278), 0.5 mg
per ml of hydrocortisone (Sigma, H-0888), 100 ng per ml of cholera toxin (Sigma,
C-8052), and penicillin/streptomycin (Invitrogen, 15070-063). To treat cells with
4OH-TAM or EtOH, 50% confluent cells were plated and allowed to adhere for at
least 24 h before treatment with 1 mM 4OH-TAM (Sigma, H7904) or with identical
Table 1 | EVL predominantly accumulates in luminal A DCIS.
A Count (%) P-values
Normal DCIS IDC
EVL
Pos 1 (4.2) 51 (56.0) 61 (40.7) o0.0001
Neg 23 (95.8) 40 (44.0) 89 (59.3)
Total 24 (100) 91 (100) 150 (100)
B EVL classification—DCIS
Count (%) P-values
Neg Pos
ER
Neg 15 (38.5) 7 (14.0) 0.008
Pos 24 (61.5) 43 (86.0)
Total 39 (100) 50 (100)
HER2
Neg 29 (74.4) 48 (96.0) 0.003
Pos 10 (25.6) 2 (4.0)
Total 39 (100) 50 (100)
K5
Neg 34 (87.2) 49 (98.0) 0.043
Pos 5 (12.8) 1 (2.0)
Total 39 (100) 50 (100)
P-Cad
Neg 27 (69.2) 48 (98.1) 0.001
Pos 12 (30.8) 1 (2.0)
Total 39 (100) 50 (100)
Subtype
Luminal A 21 (53.8) 46 (92.0) 0.002
Luminal B 5 (12.8) 1 (2.0)
HER-2 OE 5 (12.8) 1 (2.0)
Basal 6 (15.4) 1 (2.0)
Ind. 2 (5.1) 1 (2.0)
Total 39 (100) 50 (100)
Grade
Low 10 (25.6) 20 (40.0) 0.016
Inter 11 (28.2) 21 (42.0)
High 18 (46.2) 9 (18.0)
Total 39 (100) 50 (100)
Inflammation
0 1 (5.3) 7 (30.4) 0.091
1 13 (68.4) 13 (56.5)
2 5 (26.3) 2 (8.7)
3 0 (0.0) 1 (4.3)
Total 19 (100) 23 (100)
(A) Number of EVL-positive and -negative cases in normal human breast tissue (normal), DCIS
and IDC. Statistical significance was calculated using the w2-test. (B) Association of EVL
expression with clinicopathological features and breast carcinomas molecular subtypes in DCIS.
See also Supplementary Table 3.
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volume of EtOH for the time periods indicated in the text. For YAP/TAZ
localization assessment, cells were cultured in plain DMEM/F12 during the whole
course of the experiments. Plain DMEM/F12 cell culture medium, containing
EtOH alone or 4OH-TAM diluted in EtOH, was replaced 4, 8 and 12 h after the
beginning of the experiments. To assess ERK activation and Cyclin D1 expression,
cells were serum-starved for 16 h in plain DMEM/F12, before treatment with
DMSO or 2.5 mM of the MEK inhibitor PD184352 (Sigma, PZ0181) or 10 mM of
Blebbistatin (Sigma, B0560), or without any additive for 1 h. Culture medium was
then replaced with plain DMEM/F12, containing EtOH or 4OH-TAM, and DMSO
or 2.5 mM of PD184352 or 10mM of Blebbistatin or without any additive, before
analysis 12 h later.
3D matrigel cultures. Lab-Tek II plates (Lab-Tek II, #155409) were coated with
20ml Matrigel (BD Biosciences, 356231). A total of 1,000 cells were suspended in
100ml Matrigel and overlaid in wells. After polymerization at 37 C, 500 ml of cell
culture media was added and replaced every 3 days. Cells were grown for 14 days
and treated with cell culture medium containing serum, growth factors and EtOH
or 4OH-TAM. Acini were imaged by transmitted light and DIC optics for max-
imum contrast using a Leica DMI6000 inverted microscope coupled to a Hama-
matsu Orca Flash 4.0 sCMOS camera with a Leica 10 0.3 numerical aperture
PLAN FLUOR dry objective. Image processing and analysis were performed using
Fiji (ImageJ package distribution). For size quantification, acini edges were outlined
using the Find Edges function, converted to a binary mask before measurement
using the area function.
Time-lapse imaging. For time-lapse imaging, samples were maintained at 37 C in
a controlled unit with 95% relative humidity, 5% CO2. Transmitted light DIC
images were acquired on a Yokogawa CSU-X Spinning Disk confocal scan head,
coupled to a Nikon Ti microscope, using a 10 0.3 numerical aperture objective,
with an Andor iXonþ EMCCD camera at 30 or 15min (min) intervals for a
period of 60 h for 3D Matrigel culture or 2D, respectively. Images were acquired
using MicroManager 1.4.15 acquisition software. Processing and compression were
performed using Fiji. To quantify cell velocity, cell tracking was performed using
the Manual Tracking plugin function available in the Fiji software package
(quote: http://imagej.net/Citing). Total track length of cell movement was mea-
sured and used to quantify the average velocity of each cell per condition.
Immunofluoresence analysis and quantifications. For wing imaginal discs,
staining was performed by dissecting larvae in phosphate buffer at pH 7 (0.1M
NA2HPO4 and 0.1M NAH2PO4 at a 72:28 ratio). Discs were then fixed in 4%
formaldehyde in PEM (0.1M PIPES (pH 7.0), 2mM MgSO4, 1mM EGTA) for
15–30min, rinsed in phosphate buffer 0.2% Triton for 15min and incubated
overnight with mouse anti-Ena (1:50, 5G2, Developmental Studies Hybridoma
Bank; 1:50) at 4 C. Discs were then rinsed three times for 10min in phosphate
buffer 0.2% triton, incubated for 1 h with TRITC Donkey anti-mouse (Jackson
ImmunoResearch, 715-025-150) in phosphate buffer 0.2% triton supplemented
with 10% horse serum and rinsed three more times for 10min before being
mounted in Vectashield (Vector Labs, H-1000). For Phalloidin staining, discs were
dissected in phosphate buffer at pH 7 (0.1M NA2HPO4 and 0.1M NAH2PO4 at a
72:28 ratio). Discs were then fixed in 4% formaldehyde in PEM (0.1M PIPES
(pH 7.0), 2mM MgSO4, 1mM EGTA) for 15–30min, rinsed in phosphate buffer
0.2% Triton for 15min and incubated for 1 h at room temperature with Rhoda-
mine-conjugated Phalloidin (Sigma, P-1951) at 0.3mM in phosphate buffer 0.2%
triton X-100 supplemented with 10% horse serum before being rinsed and
mounted in Vectashield (Vector Labs, H-1000). Fluorescence images were obtained
with an LSM 510 Zeiss or Leica SP5 live confocal microscope using a  10 or  20
dry objective. The NIH Image J program was used to quantify wing disc area. Each
disc was outlined and measured using the Area function, which evaluates size in
square pixels. To quantify the ratio of the nub4GFP domain over the total wing
disc area, the ratio between the area of the GFP domain and the area of the whole
disc domain, measured using the Area function for each disc, was calculated.
MCF10A cells were plated in poly-L-lysine-coated coverslips (Sigma, P-8920).
To stain cells with the anti-b-CYA and anti-g-CYA, epithelial cell monolayers were
fixed with prewarmed 1% paraformaldehyde in DMEM for 30min, followed by
5min permeabilization with methanol at  20 C. Cells were then rinsed slowly
with sequential methanol dilution in phosphate-buffered solution (PBS). For all
other fluorescence staining, cells were fixed in 4% paraformaldehyde in PBS at pH
7 for 10min and permeabilized with TBS-T (TBS—0.1% Triton X-100) at room
temperature. For all staining, cells were blocked in TBS-T supplemented with 10%
BSA for 1 h at room temperature. Primary antibodies were incubated overnight at
4 C in blocking solution. Coverslips were then washed three times with TBS and
incubated with secondary antibodies and with Rhodamine-conjugated Phalloidin
(Sigma, P-1951) at 0.3mM in blocking solution for 1 h at room temperature. After
three washes in TBS, cells were stained with 2 mgml 1 DAPI (Sigma, D9542) for
5min in TBS, washed again with TBS and mounted on Vectashield. The following
primary antibodies were used: anti-EVL (1:50; Sigma, HPA018849), anti-activated
Src (1:100; Invitrogen, 44-660G), anti-phospho-Myosin Light Chain 2 (Thr18/
Ser19) (1:200; Cell Signaling, 3674), anti-Paxillin (1:200; BD Pharmingen, 610051),
anti-b-CYA (1:50; mAb 4C2, IgG1, a gift from C. Chaponnier24), anti-g-CYA
(1:100; mAb 2A3, IgG2b, a gift from C. Chaponnier24) and anti-YAP (1:200; Santa
Cruz Biotechnology, sc101199). The secondary antibodies used to detect anti-b-
CYA and anti-g-CYA were anti-mouse IgG1 FITC-conjugated (1:50; Invitrogen,
A21240) and anti-mouse IgG2b alexa 647-conjugated (1:50; Invitrogen, A21141),
respectively. The secondary antibodies used to detect all other primary antibodies
were IgG TRITC or FITC or Alexa Fluor 647-conjugated (1:200, Jackson
Immunoresearch). Fluorescence images were obtained on a Leica SP5 confocal
coupled to a Leica DMI6000, using the 63 1.4 HCX PL APO CS Oil immersion
objective. Quantifications of stress fibres anisotrophy were performed using Fibril
Tool plugin for NIH Image J program, where each individual cell was outlined and
considered as the region of interest. For quantification of cell fraction with high
basal F-actin levels, images were processed and analysed using Fiji. For each cell,
the DAPI channel was used to outline the nucleus area. Quantification of F-actin
intensity signal was performed for each cell within the nucleus area on projected
images of the basal cell surface. The F-actin signal intensity of each cell was then
semi-quantitatively scored. Cells were considered negative if their F-actin signal
intensity was lower than the average of the five lowest F-actin intensity values. Cells
were considered positive if their F-actin signal intensity was higher than three times
the average of the five lowest F-actin intensity values. For quantification of YAP/
TAZ localization, cytoplasmic localization was defined, as YAP/TAZ was
completely absent in the nucleus.
shRNA adenovirus infection and number of cells. ER-Src cells were plated in
six-well plates to reach 30% confluence by the time of infection. shEVL or shScr
virus-containing media were added at a multiplicity of infection of 103 plaque-
forming unit per cell, reaching 100% of efficiency of gene delivery. Media were
changed after 24 h. Treatments with cell culture media containing EtOH or 4OH-
TAM were performed 72 h after infection.
EVLshRNA#1: 50-GCCAAATGGAAGATCCTAGTACTCGAGTACTAGGAT-
CTTCCATTTGGC-30;
Normal epithelia DCIS IDC
Low Src activity
EVL
OrganizationStress
fiberes
Stress
fiberes
Cell
stiffening
pERK
Sustain proliferation Migration
High Src activity
Figure 9 | Model by which stress fibre and cell stiffening sustain proliferation. Early during cellular transformation, low Src activity promotes stress fibre
assembly and upregulates EVL. Organization of these fibres by EVL leads to cell stiffening. Both EVL and myosin II-dependent cell stiffening potentiates
ERK activity, sustains cell proliferation, as well as enhance Src activation. Later during transformation, higher Src activity, in addition to a reduction in
EVL levels, would disassemble stress fibres to facilitate cell migration.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15237
14 NATURE COMMUNICATIONS | 8:15237 | DOI: 10.1038/ncomms15237 | www.nature.com/naturecommunications
EVLshRNA#2: 50-ACGATGACACCAGTAAGAAATCTCGAGATTTCTTAC-
TGGTGTCATCG-30 ;
ShScr: 50-GACACGCGACTTGTACCACTTCAAGAGAGTGGTACAAGTC-
GCGTGTCTTTTTTACGCGT-30 .
The number of cells for each experimental condition was quantified 36 h after
treatment using the Scepter 2.0 Handheld Automated Cell Counter.
Soft agar colony assay. Cells (5 103) in cell culture media containing no EGF
were mixed with 0.36% gelling agarose (Sigma, A9045) and plated on top of a
solidified layer of 0.7% agarose in cell culture media with no EGF. Cells were fed
every 6–7 days with cell culture media with no EGF. The number of colonies was
counted 15–21 days later.
Immunoblotting analysis and quantification. Protein extracts from MCF10A
cells were obtained by scraping cells in TRIS lysis buffer, containing protease
(Roche, cOmplete Tablets, 4693159001) and phosphatase (Roche, PhosSTOP
Tablets, 4906837001) inhibitors, and lysed for 20min on ice. Protein extracts from
wing imaginal discs were obtained by dissecting discs in phosphate buffer at pH 7
(0.1M NA2HPO4 and 0.1M NAH2PO4 at a 72:28 ratio). Discs were then lysed in
10ml 2% SDS. Sample Buffer 2 was then added to cells or wing imaginal disc
lysates before boiling the mixture for 5min and clearing by centrifugation at
16,168 g at 4 C for 30min. Protein was resolved by SDS–PAGE electrophoresis
and transferred to PVDF membranes (Amersham Pharmacia, 10600023). Mem-
branes were blocked with 5% milk in TBS 0.1% Tween 20 and incubated with the
following: rabbit anti-activated Src (1:1,000; Invitrogen, 44-660G), rabbit anti-EVL
(1:250; Sigma, HPA018849), rabbit anti-GAPDH (1:2,000; Santa Cruz, 2D4A7),
mouse anti-phospho-p44/42 MAPK (1:2,000; Cell Signaling, 9106), rabbit anti-p44/
42 MAPK (1:1,000; Cell Signaling, 9102), rabbit anti-phospho-Myosin Light Chain
2 (Ser19) (1:500; Cell Signaling, 3671), rabbit anti-Actin (1:500; Sigma, A2066),
mouse anti-Ena (1:200; Developmental Studies Hybridoma Bank, 5G2) and rabbit
anti-a-Tubulin (1:1,000; Sigma, T6199). The specificity of the anti-Ena antibody has
been verified on wing disc extracts carrying UAS-enaS187A (ref. 51) and nub-Gal4.
Detection was performed by using HRP-conjugated antisera (Jackson Immunoresearch)
and Enhanced Chemi-Luminescence (ECL) detection (Thermo Scientific, 32106).
Western blots were quantified using the Image Studio Lite program. Uncropped
scans of the most relevant western blots can be found in Supplementary Fig. 7.
Real-time PCR analysis. One microgram of purified RNA samples was reverse-
transcribed using intron–exon-specific primers. Real-time qPCR were performed
using PerfeCTa SYBR Green FastMix (Quanta Biosciences) in 384-well plates in
the Bio-Rad, #1725125. The relative amount of EVL, Cyclin D1, CTGF or
ANKRD1 mRNA was calculated after normalization to the GAPDH transcript.
Primers used for EVL were 50-GAAGAGTCCAACGGCCAGAA-30 and 50-
ACTGGGAGGCTGCTTTTCTC-30 . Primers used for GAPDH were 50-CTCTGC-
TCCTCCTGTTCGAC-30 and 50-ACCAAATCCGTTGACTCCGAC-30 . Primers
used for CTGF were 50-CTCGCGGCTTACCGACTG-30 and 50-GGCTCTG-
CTTCTCTAGCCTG-30. Primers used for ANKRD1 were 50-TAGCGCCCGA-
GATAAGTTGC-30 and 50-GGTTCAGTCTCACCGCATCA-30 . Primers used for
Cyclin D1 were 50-GATCAAGTGTGACCCGGACTG-30 and 50-CCTTGGGGTC-
CATGTTCTGC-30 .
Cell cycle profile. Sub-confluent cells were cultured overnight in media without
EGF. Cells were then incubated in culture media containing EGF and EtOH or
4OH-TAM for 12 h, fixed with 70% EtOH and stained with 10 mgml 1 of pro-
pidium iodide (Sigma, P4170). Cell cycle profiles were obtained using FACS
Calibur. Flow Logic software was used for quantification of the percentage of
S-phase cells.
G/F actin assay. The G-actin/F-actin In vivo Assay Kit (Cytoskeleton, Denver,
CO, USA, BK037) was used to quantify the F- and G-actin pools. Cells were
harvested by scraping in lysis buffer. Cell lysates were then incubated for 10min at
37 C and centrifuged at 350 g at room temperature for 5min to pellet unbroken
cells. Supernatants were then centrifuged at 90,000 g for 90min at room tem-
perature to pellet F-actin and leave G-actin in the supernatant. Supernatants were
then removed and kept on the side in 5 SDS sample buffer, while pellets were
incubated in F-actin depolymerization buffer on ice for 1 h to allow actin depo-
lymerization to occur before the addition of 5 SDS sample buffer. G- and F-actin
fractions were then analysed by immunoblotting analysis and quantified using the
Image Studio Lite program, as the ratio between F- and G-actin levels for each
experimental condition.
Atomic force microscopy. For the AFM indentation experiments a Nanowizard I
(JPK Instruments, Berlin) equipped with a CellHesion module was used. Arrow-T1
cantilevers (Nanoworld, Neuchatel, Switzerland) were modified with polystyrene
beads (radius 2.5 mm, Microparticles GmbH, Berlin, Germany) with the aid of
epoxy glue to obtain a well-defined spherical indenter geometry and decrease local
strain during indentation. The cantilever was lowered with a speed of 5 mms 1
until a relative set point of 2.5 nN was reached. The resulting force distance curves
were analysed using JPK image processing software (JPK instruments). Force
distance data were corrected for the tip sample separation and fitted with a Hertz
model for a spherical indenter to extract the apparent Young’s Modulus68.
A Poisson ratio of 0.5 was assumed. A 2-h time window was required for
measurement of each experimental condition.
Real-time deformability cytometry. A microfluidic chip was made out of PDMS
using soft-lithography and sealed with a glass coverslip after plasma surface acti-
vation. The microfluidic chip consisted of two reservoirs connected by a 300-mm-
long constriction channel with a 30 mm by 30mm cross-section. A row of filter posts
at the inlet prevents the channel from clogging by cell clumps and debris. For
measurement, cells were re-suspended in a 0.5% methylcellulose solution in PBS at
a concentration of 4–5 106 cells per ml. The cell suspension was drawn into 1ml
syringes and connected to the chip by polymer tubing. Cells were pumped with a
syringe pump at a constant flow rate of 0.16 ml s 1 (0.04 ml s 1 sampleþ 0.12
ml s 1 sheath) for 2min before collecting data, to stabilize flow. Data (typically, a
minimum of 2,000 events) were acquired in real time with a high-speed CMOS
camera (MC1362; Mikrotron, Unterschleissheim, Germany), operating at
2,000 f.p.s., and illuminated by a high-power LED (CBT-120, 462 nm; Luminus
devices, Woburn, MA, USA) through a  40 objective of an inverted microscope
(Axiovert 200M, Carl Zeiss, Oberkochen, Germany) at the end of the 300-mm-long
constriction channel where the cell shape had reached steady state. An image-
processing algorithm implemented on Cþþ LabVIEW was used to determine the
cell cross-sectional area and circularity, defined as c ¼ 2 ffiffiffiffiffiffipAp =l, where A is the
projected area of the cells and l its perimeter. An analytical model69 was used to
calculate the hydrodynamic flow profile around a moving cell in confinement,
couple the resulting surface stress to a linear elastic model of a homogeneous
isotropic sphere, and extract the elastic modulus for comparison with the observed
cell parameters, assuming a constant viscosity of the surrounding fluid of 15mPa.
Breast carcinoma series. Formalin-fixed and paraffin-embedded breast tumour
samples were obtained from a Pathology Laboratory of Arac¸atuba (Veronese
Patologia e Citologia Arac¸atuba, Brazil), under patient informed consent and with
ethical approval by the lab research review boards, implying that the spare biolo-
gical material, which has not been used for diagnosis, could be used for research.
This is in accordance with the national regulative law for the handling of biological
specimens from tumour banks, being the samples exclusively available for research
purposes in retrospective studies, as well as under the International Helsinki
Declaration. All breast tumour cases were previously characterized with regard to
ER, progesterone receptor (PR), epidermal growth factor receptor (EGFR), HER2,
CK5, P-cad and the antigen Ki-67, in addition to patients’ age and clin-
icopathological features, such as grade, tumour infiltrating lymphocytes
(inflammation) and lymph nodes status. Breast tumour components were classified
into luminal A and B, HER2-overexpressing, and basal-like carcinomas, according
to the immunoprofile70. Twenty-four cases of normal breast samples derived from
reduction mammoplasties or adjacent to tumour tissue were included in this study.
All morphological and immunohistochemical assessments were conducted by a
pathologist (AP). The study was conducted under the national regulative law for
the handling of biological specimens from tumour banks, the samples being
exclusively available for research purposes in retrospective studies.
Immunohistochemistry and quantification. IHC was performed using the
Ultravision Detection System Anti-polyvalent HRP (Lab Vision Corporation) for
EVL. Antigen unmasking was performed using a commercially available solution of
citrate buffer, pH 6.0 (Vector Laboratories), at a dilution of 1:100 at 98 C for
30min. After the antigen retrieval procedure, slides were washed in PBS and
submitted to blockage of the endogenous peroxidase activity by incubation in
methanol (Sigma-Aldrich) containing 3% hydrogen peroxide (Panreac). Slides were
further incubated with the primary antibody for EVL (1:100; Sigma, HPA018849).
The IHC reaction was revealed with diaminobenzidine (DAB) chromogen
(DakoCytomation). The positive control was a tonsil sample, which was included
in each run, to guarantee the reliability of the assays. Non-neoplastic breast tissues,
as well as normal breast surrounding the neoplastic cells, were considered internal
controls. EVL expression was mainly found in the cell cytoplasm. The normal
breast tissue and each component of breast carcinoma were semi-quantitatively
scored with regard to the intensity (I) of staining as negative (0, no staining), weak
(1, diffuse weak), moderate (2, moderate staining) or strong (3, defined as
strong staining), and the extent (E) of stained cells was evaluated as a percentage.
For each case, a staining score was obtained by multiplying I x E (range 0-300).
Cases with a staining score r100 were considered negative and cases with a score
4100 were classified as positive. The TMA cores measured 2mm in diameter and
included a representative area of the tumour; up to three cores of each case were
represented in the TMA. In the cases where in situ and invasive carcinomas were
present in the same core (n¼ 71), the samples were classified using the
nomenclature increase/decrease/equal EVL expression according to the change in
IxE score.
Sample size. No statistical methods were used to predetermine the sample size.
Microarray data of 903 neoplastic breast lesions, including 12 ERþ ADH, 22 ERþ
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DCIS, 68 ERþ IDC1, 189 ERþ IDC2, 273 ERþ IDC3, 44 ER IDC2 and 299
ER IDC3, were compared to microarray data of 255 normal breast tissues. For
Drosophila wing disc growth measurements, 101 samples from four independent
nub-Gal4, UAS-GFP4UAS-Src64BUY1332, UAS-p35 crosses (biological replicates)
were analysed. For all other crosses, 17–96 samples from two independent crosses
(biological replicates) were analysed. Three biological replicates were used for
quantification by western blots of pERK, total ERK, pMLC, ER-pSrc, EVL, Ena or
actin levels. Six biological replicates were used for quantification of ER-pSrc in
ER-Src cells treated with EtOH or TAM for 4, 12, 24 or 36 h. Quantification of EVL
protein levels in ER-Src cells knocked down for EVL was carried out from one
biological replicate. Protein extracts from wing imaginal discs were obtained by
dissecting four discs per genetic background from two independent crosses
(biological replicates). To quantify actin levels or F-/G-actin ratio, three biological
replicates were used in triplicate (technical replicates). Quantifications of Cyclin
D1, EVL, CTGF or ANKRD1 mRNA levels were from three technical replicates,
repeated three times (biological replicates). Three biological replicates were used to
quantify cell number or number of cells in S-phase of the cell cycle. Quantifications
of acini size were from two biological replicates. Quantifications of number of
colonies in soft agar were from three biological replicates in triplicate (technical
replicates). For quantification of fibre anisotropy, between 90 and 103 cells from
three biological replicates were analysed per experimental condition. To quantify
the fraction of cells with high basal F-actin levels, 140 to 220 cells from two
biological replicates were used. To quantify cell velocity, 100–200 cells from three
biological replicates were tracked per condition. To quantify YAP/TAZ localiza-
tion, eight fields per experimental conditions from two biological replicates were
used. A total of 160 (2D) or 100 cells (3D) per experimental conditions from three
(2D) or two (3D) biological replicates were used to measure stiffness by AFM. Two
biological replicates per condition were used to measure stiffness by RT-DC. The
archive of breast tumour samples includes 150 invasive breast carcinomas and
91 in situ carcinomas, from which areas of in situ and invasive carcinoma can be
found in the same block for 71 patients. In addition, 24 normal breast samples were
used for comparison.
All experiments were considered for quantification, with the exception of two.
For quantification of ER-pSrc levels during the 36 h of cellular transformation,
blots with a high degree of variance in GAPDH levels between samples or in
ER-pSrc levels between biological replicates were excluded. For quantification of
pMLC between ER-Src cells treated with EtOH or TAM for 12 h, three biological
replicates, which did not show an increase in ER-pSrc levels and endogenous pSrc,
were excluded. Blinding was used to quantify YAP/TAZ localization. No other
quantification used blinding. Randomizations were used to quantify fibre
anisotropy and the fraction of cells with high basal F-actin levels by selecting each
field using the DAPI channel exclusively.
Statistics. Statistical analyses of EVL expression in normal, DCIS and IDC
samples were conducted using IBM SPSS Statistics (Version 22.0. Armonk, NY:
IBM Corp). The associations between categorical variables were tested for statistical
significance using the chi-square test to compare multiple conditions or using
Fisher’s exact tests to compare two conditions. Both tests evaluate the strength of
the association between two categorical variables. A two-tailed significance level of
5% was considered statistically significant (Po0.05). Other statistical analyses were
performed using Prism 6.0 software (GraphPad Inc.). For statistical comparison of
two independent groups (Figs 1e,f,2i and 4b,c,g; and Supplementary Figs 2C and 5)
the unpaired t-test were used. For statistical comparison between more than two
groups (Figs 1a,f,g,2b–d,5b–h,6e,f and 7b–e; Supplementary Figs 2B,3,6B,C,E,F),
one-way ANOVA tests were used. For statistical comparison of the percentage of
S-phase cells between EtOH- and TAM-treated ER-Src cells over time (Fig. 1d and
Supplementary Fig. 2A), two-way ANOVA tests were used. To detect differences in
EVL protein levels across multiple test attempts between EtOH- and TAM-treated
ER-Src cells during the 36 h of cellular transformation, a Friedman test was used.
For statistical comparison of gene expression profiles between normal breast
samples and breast tumour samples of different stages, grades and ER status, the
LIMMA (Linear Models for Microarray Data) algorithm was used to calculate fold
change (Log2R), B-statistics (lods), t-statistics and p-values. Genes selected as
differentially expressed were those with a lods value higher than 0: that is, the
probability of being differentially expressed was higher that 50% (ref. 71). Statistical
significance of apparent Young’s moduli between EtOH- and TAM-treated ER-Src
cells for each time point (Fig. 2f,g) was calculated using a simple Mann–Whitney
test or the Kruskal–Wallis test with multiple comparisons for ER-Src cells
expressing shScr or shEVL and treated with EtOH or TAM for 12 h. For RT-DC,
statistical analysis was performed using linear mixed models. This approach allows
the comparison of different treatment states, considering the reproducibility of the
effect. We defined a model that allows an individual mean for each biological
replicate (random intercept). In addition, the difference between the compared
treatment states (ETOH and TAM) was allowed to be different for each replicate
(‘random slope’). This model was then compared to a so-called ‘Null model’, which
assumes that there is no difference between the treatment states. A likelihood ratio
test and Wilks theorem were used to quantify the similarity of the two models,
using a p value. The P-value indicates whether the null hypothesis that both models
are identical is true.
Data availability. Microarray data of genes deregulated in TAM-induced ER-Src
cells18 have been deposited at GEO under accession number GSE17941. Affimetrix
platforms used in this study were HG-U133A and HG-U133A PLUS 2.0.; series
accession numbers were GSE15852, GSE16873, GSE7390, GSE20194, GSE10810,
GSE21422, GSE22544, GSE23593, GSE5460, GSE5764, GSE10780, GSE2109,
GSE3744, GSE17907, GSE19615 and GSE23177. See also Supplementary Table 1.
All other remaining data are available within the Article and Supplementary Files,
or available from the authors upon request.
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